This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $249,276 to the University of San Francisco (USF) to assess the real-world effectiveness of maternal respiratory syncytial virus (RSV) vaccination. The project aims to evaluate the impact of the recently licensed maternal RSV vaccine in preventing RSV-associated lower respiratory tract infections (LRTIs) in infants,...
This federal Project Grant award of $883,864 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to develop a thermostable measles fusion (F) glycoprotein vaccine strategy. The key objectives are to engineer a thermostable measles F protein immunogen and evaluate the protective immune responses it elicits, with the goal of creating a vaccine that is safe and effective for...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $464,750 to the Icahn School of Medicine at Mount Sinai to investigate the mechanisms of mucosal immune responses induced by mRNA-based and Newcastle Disease Virus (NDV)-based COVID-19 vaccine platforms. The research aims to understand how these vaccine technologies can prime mucosal B cells and promote their recirculation to induce...
This Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of novel multivalent mucosal vaccines for human noroviruses (HuNoVs). The $798,173 award to The Ohio State University aims to create two candidate vaccines: an oral multivalent rotavirus (RV)-based HuNoV vaccine and an intranasal multivalent measles/mumps/rubella (MMR)-based HuNoV vaccine. The goal is...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $910,905.00 to the Scripps Research Institute to advance HIV vaccine development using a lipid nanodisc platform. The key objectives are to: Solve the structures of engineered transmembrane HIV envelope (Env) proteins incorporated into lipid nanodiscs in complex with broadly neutralizing antibodies targeting the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $390,942 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Georgia Tech Research Corp to develop self-assembled peptide nanoparticles as a universal influenza vaccine platform. The goal is to use these nanoparticles to present conserved viral antigens, including hemagglutinin stalk, matrix protein 2 ectodomain, and nucleoprotein, in order to elicit broad, protective immune...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $261,846 to New York Medical College to develop an intranasal vaccine against Pseudomonas aeruginosa (PA), a common cause of healthcare-associated infections. The research aims to create a multi-valent vaccine using tobacco mosaic virus as a delivery platform, with the goal of providing broad protection against different...
This National Science Foundation Project Grant of $255,927 awarded to Invvax, Inc. on March 1, 2022 seeks to develop stable prophylactic antibodies through February 2023. Funded through the NSF Engineering Directorate's CFDA 47.041 program, this Small Business Innovation Research Phase I project will engineer mutations to antibody Fc regions to resist degradation and enhance binding to the neonatal Fc receptor for potentially decades-long duration. Specifically, the awardee will combine known...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop new malaria vaccine candidates based on the Pf Glutamic Acid Rich Protein (PFGARP) antigen. The $412,500 award will be used by the University of South Florida to evaluate immunodominant fragments of PFGARP for potential inclusion in a malaria vaccine, with a focus on improving efficacy against the deadly Plasmodium...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Orlance, Inc., a woman-owned small business, a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop an enhanced seasonal influenza DNA vaccine. The project aims to combine the advantages of a closely matched seasonal influenza vaccine with a universal influenza vaccine to provide more robust and durable protection, especially for the elderly and immunocompromised...